Ariad Investors have to hope that if EU doctors are, by and large, more sophisticated, that will translate into stricter adherence to newly advanced switch criteria,
and that this factor will sufficiently offset greater cost consciousness in the EU.
I'm hopeful, because this kind of approach would play to Iclusig's biggest advantage:efficacy.
IAndy, since many KOL's in EU and USA are moving to using second generation CML drugs first line, shouldn't you consider Pona as a "second" line treatment as well, instead of your message calling Ariad a third line drug? I don't think it is..
Market Data 
Markets 
AI
